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Abstract 
The type I transforming growth factor-13 (TGF-13) receptors are serine/threonine kinases that are essential for the action of TGF-13. In 
this paper, we describe the molecular cloning and expression of the R4/ALK5 human type I TGF-13 receptor promoter. DNA sequence 
analysis indicates that the promoter lacks a TATA and CAAT box but is highly GC-rich and contains putative Spl binding sites. The 
transcriptional start site is approx. 232 base pairs upstream of the AUG start codon. In human lung fibroblasts, TGF-13 induced a 3-fold 
increase in steady-state l vel for type I receptor mRNA. Exposure of cells transfected with a 618 bp promoter fragment o TGF-131 
up-regulated transcriptional ctivity indicating that a TGF-13 response lement is contained within this region. 
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1. Introduction 
Transforming rowth factor-13 (TGF-13) is a multifunc- 
tional cytokine that has important functions regulating 
growth, development, immune function, and wound heal- 
ing [1-4]. Although TGF-13 binds to several surface recep- 
tors, the expression and function of both type I and type II 
receptors are required for signaling [4-8]. Both receptor 
types belong to a large family of transmembrane 
serine/threonine kinases. Only one functional type II re- 
ceptor for TGF-~ has been identified (RII) [8]. In contrast, 
there are several structurally similar type I receptors in- 
cluding R4/ALK5 (RI R4) [5], R1/Tsk7L [9,10], and 
R3/TSR1 [11]. RI R4 mediates TGF-13 signal in MvlLu 
epithelial cells. Tsk7L transduces TGF-13 signal in a murine 
epithelial cell line (NmuMG) [10]. To date, the signaling 
function of TSR1 has not been defined. 
Type I receptors can only bind TGF-13 when co-ex- 
pressed with type II receptors. TGF-[3 signaling requires 
the presence of a functional type I kinase domain [4,6,7]. 
Abbreviations: TGF-13, transforming growth factor-13; RI  R4 , type I 
receptor R4/ALK5; RII, type II TGF-13 receptor; UTR, untranslated 
region. 
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The cytoplasmic domain of RII undergoes autophospho- 
rylation independent of ligand [11,12]. Although the exact 
signaling events remain unclear, there is evidence that the 
association of a type I receptor with RII leads to transphos- 
phorylation of the type I receptor by the RII kinase [11-13]. 
Replacement of a threonine residue with aspartate in the 
GS domain of RI R4 produces a constitutively active type I 
TGF-13 receptor kinase which transduces anti-proliferative 
and transcriptional responses in mutant MvlLu cells in the 
absence of ligand or type II receptor [14]. 
Changes in TGF-13 receptor expression has significant 
physiologic effects. In a variety of human cancer cell lines, 
down-regulation or loss of type II TGF-13 receptors leads 
to dysregulation of growth [3,4,15-17]. Furthermore, spe- 
cific effector substances induce alterations in receptor ex- 
pression and subsequently change cellular responsiveness 
to exogenous TGF-131. For example, RII is down-regulated 
by 1,25-dihydroxyvitamin D 3 in osteoblastic cells and by 
fibroblast growth factor in bovine aortic cells [18,19]. Type 
I receptor expression is down-regulated by interferon-~/ 
and lipopolysaccharide in human monocytes [20]. 
Prostaglandin E 2 down-regulates RI  R4 message in human 
lung fibroblasts [21]. Examination of the transcriptional 
elements of TGF-~ receptors may allow investigation con- 
cerning regulation of these receptors. 
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2. Materials and methods 
2.1. Library screening 
Approx. 10 6 plaques of a lambda FIX human lung 
fibroblast genomic DNA library (Stratagene) were trans- 
ferred to nylon filters (MSI) and screened with a DNA 
fragment containing 251 bp (nucleotides -5  to 246) near 
the 5' end of the coding region for the RI R4 [5]. The DNA 
fragment was labeled with [32p]dCTP (New England Nu- 
clear) by random priming (New England Biolabs). Hy- 
bridization was done for 18 h at 43°C in 50% formamide, 
5 × SSPE, 5 X Denhardt's, 0.2% SDS, and 100 Ixg/ml 
denatured salmon sperm DNA. Purified clones were 
screened with oligonucleotides labeled with 32 P[dCTP] and 
terminal deoxynucleotidyl transferase (United States Bio- 
chemical). Phage DNA was isolated and digested with 
several restriction enzymes. DNA fragments hybridizing to 
an oligonucleotide containing the Y-end of the RI R4 cDNA 
were subcloned into pBluescript. 
Downstream primers for RI R4 luc 1 5'-CCCAAGCTTCCT- 
TTGTAACTGCTCGGAGG, RIRgluc2 5'-CCCAAGCT- 
TGCAGCCAATCCGCAGC-3', and RIa41uc3 5'-CC- 
CAAGCCTCGATCGGCTCCCGG CTCCGAG-3' con- 
tained a Hin dIII restriction site. Reactions were performed 
with 60 s denature at 94°C, 43 s anneal at 60°C, 60 s 
extension at 72°C, and 35 cycles. After restriction diges- 
tion and ligation to the prepared pGL2-Basic vector, plas- 
mid DNA was prepared by the CsC1 method and se- 
quenced to prove absence of PCR error. Transfections 
were performed by calcium precipitation as previously 
described [22]. Plates were cotransfected with RSV-[3- 
galactosidase plasmid to control for transfection efficiency 
[23] and grown in media containing I0% fetal calf serum. 
At 48 h 2 ng/ml TGF-[31 (R and D Systems) was added to 
experimental plates. At 72 h, cells were harvested and 
luciferase activity and [3-galactosidase activity was mea- 
sured [24]. 
2.4. Primer extension analysis 
2.2. DNA sequencing 
DNA sequencing was performed on double stranded 
plasmid DNA by the dideoxy chain termination method 
using T7 polymerase (Sequenase, United States Biochemi- 
cal). Compressions were resolved by repeating the reaction 
with deaza-7 dGTP or the use of thermal cycling (New 
England Biolabs). Both strands of the DNA were se- 
quenced. Sequencing alignments and analysis were per- 
formed with Geneworks oftware. 
2.3. Transfections and protein assays 
Human embryonic lung fibroblasts (IMR-90, Institute 
for Medical Research, Camden, N J) were transfected with 
constructs containing a fragment of the Y-flanking se- 
quence of the RI R4 gene linked to the coding region for 
firefly luciferase (pGL2-Basic, Promega.) The inserts were 
prepared by PCR with Taq polymerase and 10% DMSO as 
follows: Upstream primer 5'-CCGCTCGAGCTGGGTF- 
TGGGGTGAC-3' contained an Xho 1 restriction site. 
Transcription start site was determined by primer exten- 
sion analysis. Total RNA was prepared from IMR-90 cells 
grown in media containing 10% fetal bovine serum and 
used as a template for the reaction. The 18 nucleotide 
primer 5'-TCACCCCAGCAAACCTCG-3' located 48 nu- 
cleotides 5' to the AUG translation initiator, was 5'-32P - 
labeled using T4-polynucleotide kinase and [~-32p]ATP. 
25 fmol of the 32p-labeled primer (106 cpm) and 30 Ixg of 
total RNA were used for the extension reaction. After 
hybridization for 90 min at 50°C, the reaction was carried 
out at 42°C for 1 h with RNA reverse transcriptase (200 U) 
and 0.5 mM dNTPs in a 50 ml reaction volume. The 
extension product was analyzed on a 6% acrylamide se- 
quencing el using a known DNA sequencing product for 
size determination. 
2.5. RNA isolation and Northern analysis 
Total cellular RNA was isolated by a single-step method 
which employs guanidium thiocyanate-phenol-chloroform 
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Fig. 1. Restriction map of fragments of the RI R4 gene. Genomic fragments of RI R4 were digested with restriction enzymes and subcloned into pBluescript 
for further characterization. E = EcoRI, S = SacI. 
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RNA (10 Ixg) was electrophoresed on 1% agarose-6% 
formaldehyde gels and transferred to nitrocellulose filters. 
Equal loading of RNA was confirmed by ethidium bro- 
mide staining of ribosomal bands fractionated on agarose- 
formaldehyde gels and by probing with an oligonucleotide 
against the 18 S ribosomal subunit. Hybridization was 
performed using 0.5-1.0 X 106 cpm/lane labeled probe 
(SA, 4-10 × l0 s cpm/l~g), and the filter was washed and 
exposed to x-ray film for autoradiography at several differ- 
ent times to ensure that the bands could be quantified by 
densitometry within the linear range. 
3. Results 
The 5'-flanking region of the RI  R4 receptor was isolated 
by screening a human genomic library with a cDNA 
fragment containing 251 bp of the 5'-end of the coding 
region [5]. Three clones hybridized to an oligonucleotide 
derived from the sequence of the 5'- end of the published 
5' UTR and two others hybridized to an oligonucleotide 
derived from sequence 800 bp downstream from the trans- 
lational start site. Restriction mapping and Southern analy- 
sis of the clones hybridizing to the 5' oligonucleotides 
identified two unique overlapping clones. After restriction 
digestion, fragments were subcloned into pBluescript for 
further characterization (Fig. l). 
Analysis of 1422 bp of the DNA sequence 5' from the 
described 5'-UTR [5] indicates that the Y-flanking region 
lacks a TATA box or CAAT box (Fig. 2). This region is 
highly GC-rich and contains everal putative Spl binding 
sites and a consensus AP2 binding site. This structure is 
similar to that of several other growth factor receptors 
[26-28]. The major transcriptional start site was deter- 
mined by primer extension to be located at approx. 232 
bases upstream of the AUG start codon (Fig. 3). This 
extends the RI R4 UTR an additional 156 bp beyond that 
previously described [5]. 
To confirm that the 5'-flanking region upstream of the 
start site mediates transcriptional ctivity, constructs con- 
taining promoter f agments from the RI R4 gene were trans- 
fected into human lung fibroblasts and bovine vascular 
smooth muscle cells (Fig. 4). Luciferase activity was cor- 
rected for transfection efficiency with RSV-13-galacto- 
sidase in the three constructs. The largest of the three 
constructs (RIa41ucl) contains 5' sequence from 726 to 
109 bp upstream of the proposed start AUG codon for the 
RI R4 cDNA. This construct showed the highest luciferase 
activity in both lung fibroblasts (Fig. 5) and vascular 
smooth muscle cells (data not shown). A second construct 
- 1422  TCTCAGATCCCAGCTCCAATAT - 1401  
CCACGCL"-", -FI~C C'I-~-I-I~2ATCTCC CGGAAGGAAGC CTTCACAGGTGGGG - 1351 
AAAATGCTCACCCAGTGACTCTAAAGTAGTGCACAAATTGGCATTAATCA - 1301 
GAACCATTCTGATTCCTGCTATCAAGGTTTAJ ,~ I~I 'AATTCTAAGCTCAAAT - 1251  
GACACAGAAAATAAAATTTCCTCCTTAAAAGGTTCTGCGGAAAA TATTC - 1201  
T CTGTTCTACGTAACAGCCTC CTTGGCTGTGTTTGTGTCTGAAGAAAGGA - 1151 
CTAGTCTGACAGGAAGAATTACAAATCTGGAGCTCA' I -FF ,  ~GCGTCGCAG - 1101 
AGGGAAGGTGGGTGGAG CGTCTCGCAGTAAATTAGGAATTCAGAATGAAA - 1051 
ACGTAGAGTTTATTTGG~,-F I - I - r  rAGTGACAC CTCAGGATTATTATACAGC - 1001 
AffPGTC~GA~%.CAC-Cl' ~P*~%. ' I~-~,AC ' I~  C%'~2 C C C ~ G C - 951 
GGGAGCTGGGTGCTAAGAAGGGGGAACCCTC~GGGG~ - 901  
~ATCCTCCC-F ,  - , ,CCAACCTGGATCGGGAAGGGGTTTGAGAGGAGTG CG G - 851  
CTTGGATCCCCATCCTGGATCTGTGCTGGAGGGAGGCGGGAGGCTATTTG - 801  
G GG GTGTGTTTGGGCTCAGGATCTGGGTCTGACGCTGGGATCTGAGGACT - 751  
TTCTGGGTTTGGAACTGGGTGGGGGAGCTGGGTTTGGGGTGACCGCTGGG - 701  
AG CAG GAGGAAATAGGAGAGTGAGTC GCATGTGAAGGGCACTGAGGAGG G - 651  
ATCTTCGGGGGAATGCTGAAGTTGATGCGTGGACTTGGAGAGGGGAAGTT - 601  
GAAGTGGATGCAGGGGCCTGGCGCTGCAGCGGATCTGGGTGGCATGTGCT - 551  
GGGATTGCCAATGCGGACGTGTGAATGGGGTCAGGGTGGGGCTGAGGCAG - 501  
TACCAGATCTTCCGCGCCTAGAGGAGGTTAGAAGAAAAGAGCGTCGAACG - 451  
GCCACAGCC" , -F rF rCCGAAAGAGACTCACACAGACACACCCATCGCTCTA - 401  
CCCGGCCCTCCGGGGCTAGCGGCTGAGCGGTGCTGGGGCTGGCAGACCC~ - 351  
~2CACGCGGCC'IR2'I~GGAGCCGGGAGCCGATCGGGCCGGGGCTGGGG - 301 
TCTGGCGGCCCAGCCCCCGGGGAGCGTGG~GAAACCGGCGC - 251  
TCGCGGCTGCGGATTGGCTGCCTGGCGGGCCCGCAGGCGGGGCTCCCGGC - 201  
/ sp, | 
TGGGTCCGCTTGGCAGCTCGCGGCGGCGGGG~SGCGGGGCCGGCGGGAGC - 151  
CCGGCAGCCAATGGACGCGCGTCCTCCGAGCAGTTACAAAGGGCCGGAGC - i01  
GAGGCGCCGCGGCGGCTAGGGAGGTGGGGCGAGGCGAGGTTTGCTGGGGT 51 
GAGGCAGCGGCGCGGCCGGGCCGGGCGCCACAGGCGGTGGCGGCGGGACC 1 
ATQGAGGCGGCGGTCGCTGCTCCGCGTCCCCGGCTGCTCCTCCTCGTGCT + 50 
Fig. 2. Sequence of 5'-flanking region of the RI R4 gene. Boxed areas represent potential Spl and AP2 binding sites. 
initiation codon [5]. Small arrow indicates transcriptional start site. 
Bold text indicates translation 
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Fig. 3. Determination of the RI R4 gene's transcriptional start site by 
primer extension. Lanes 1 and 2 show primer extension reactions on RI R~ 
using primers located at 235 and 315 base pairs upstream of the AUG 
that produced no visible product. Lane 3 shows the primer extension 
reaction using a primer located at 48 bp upstream of the AUG. The major 
band localizes the start site to approximately 232 base pairs upstream of 
the AUG codon (indicated by arrow). There are two minor bands at 207 
and 197 bp upstream of the AUG. Product size was determined by 
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Fig. 5. Transcriptional ctivity of RI R4 promoter constructs. Constructs 
RIR41ucl, RIR41uc2, and RIR41uc3 were transfected into human lung 
fibroblasts and luciferase activity assessed. Values shown are luciferase 
activity above negative control, adjusted for [3-galactosidase activity. 
Mean_+l SE, n=4.  
(RIR41uc2) containing a fragment from 314 to 109 bp 
upstream from the AUG also had transcriptional ctivity. 
A construct (RIR41uc3) containing a fragment from 229 to 
109 bp upstream from the AUG and therefore missing the 
GC-rich region ( -229  to -314)  and the proposed start 
site ( -232)  did not have promoter activity. 
Expression of the type I receptor mRNA is increased by 
TGF-13 treatment in certain smooth muscle cells [29]. We 
found that TGF-13 increased expression of its own type I 
receptor mRNA in human lung fibroblasts (Fig. 6A). To 
further explore the mechanism of this induction, we em- 
ployed the RI R4 promoter constructs in transient transfec- 
tion assays in human lung fibroblasts. Luciferase activity 
in cells transfected with the RIRalucl construct increased 
I001~ 
11m~1 
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Fig. 4. Description of PCR generated fragments of the 5'-flanking region of the RI R4 gene and analysis of GC content. Translational start site indicated by 
ATG. Large arrow indicates end of published 5' UTR [5]. Transcriptional start site marked by small arrow. Three fragments of varying length were 
generated by PCR as shown. Percent GC content of the 5'-flanking sequence is graphically depicted (Geneworks oftware). 
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Fig. 6. (A) Effect of TGF-[3 on the steady-state l vels of RI R4 mRNA. 
Fibroblasts were untreated or treated with TGF-[31 (2 ng/ml). After 24 h, 
total RNA was isolated and 10 ~Lg was used for Northern analysis. The 
nylon filter was probed with a radiolabelled cDNA for the human RI R4 
and a radiolabelled oligonucleotide that identified the 18 S ribosomal 
subunit. (B) Regulation of RI R4 promoter activity by TGF-I~I. Fibrob- 
lasts were transfected with the RIR41ucl promoter fragment and were 
untreated (C) or treated with TGF-131 (2 ng/ml). Mean_+ SE, n = 4. 
2.3-fold when transfected cells were treated with TGF-13 (2 
ng/ml) for 24 h. A representative experiment is shown in 
Fig. 6B. The results of three such experiments revealed an 
increase of 230% _+ 10 (mean + 1 SE). 
4. Discussion 
We have cloned the promoter for the human R4/ALK5 
TGF-[3 type I receptor (RIR4). The promoter is highly 
GC-rich and lacks a TATA or CAAT box. A GC-rich 
region 229-314 bases prior to the translation initiation 
codon is required for transcriptional ctivity and contains 
the proposed transcriptional start site. This promoter type 
has been identified for several other genes encoding rowth 
factors and their receptors including the epidermal growth 
factor receptor [30], interleukin 1 type I receptor [31], 
human insulin receptor [32], insulin-like growth factor I 
receptor [27], luteinizing hormone receptor [28], and the 
type II human TGF-[3 receptor [26]. 
In genes of this type, translation may initiate from 
several sites within the GC-rich region. The transcription 
start site was identified by primer extension and by using 
promoter constructs of varying size. A construct missing 
the proposed start site start site did not have promoter 
activity. The full length cDNA for the RI R4 as determined 
by Northern analysis is 5.5 kB. In contrast, the described 
RI R4 cDNA [5] contains 5.3 kB and includes only 76 bases 
of 5' UTR. This size difference is consistent with the 
localization of the start site 232 bp upstream from the 
AUG. Similar to the RII gene, the RI R4 promoter contains 
several consensus Spl binding sequences. Li et al. have 
recently shown that TGF-[3 markedly up-regulates tran- 
scription of the cyclin-dependent kinase inhibitor p15 INK4B 
by means of Spl binding [33]. It is possible that the 
responsiveness to TGF-[3 that we have demonstrated in the 
RI R4 promoter is also mediated by Spl. 
There are significant differences in the structure of the 
RII and RI R4 promoters that may result in differential 
regulation of the receptors. The RI R4 promoter contains 
sequence that is extremely GC-rich (approx. 85%), more 
so than the RII promoter (approx. 70%). The RII promoter 
has at least two AP1 consensus binding sequences and no 
AP2 elements. The proximal AP1 increases transcriptional 
activity of the RII promoter in lung fibroblasts (unpub- 
lished results). In contrast, the RI R4 gene does not contain 
APl sites but does contain an AP2 binding sequence. 
Other than their general structure, there is little sequence 
homology between the two promoters and it is likely that 
different transcription factors are involved in the regulation 
of the two genes. Although often described as 'housekeep- 
ing genes', receptors for growth factors have been shown 
to be regulated by exogenous effector substances and 
regulation of genes of this type has significant functional 
consequences. 
In fibroblasts, TGF-[3 increases connective tissue pro- 
duction and up-regulates its own synthesis [34]. Our data 
shows that TGF-[3 increased the steady-state level for RI R4 
mRNA. Recent results by others showed that TGF-[3 up- 
regulated RI  R4 mRNA in human corpus cavernosum 
smooth muscle cells [29]. Employing transient ransfec- 
tions of a construct containing 618 bp of the RI R4 pro- 
moter egion and a luciferase reporter gene, we found that 
TGF-[3 increased RI R4 promoter activity 2- to 3-fold in 
lung fibroblasts. It is noteworthy that type I collagen 
accumulation is strongly up-regulated by TGF-[3 contribut- 
ing to the deposition of collagen during fibrotic reactions 
[35-37]. Recent work shows that TGF-[3 activates et2(I) 
collagen gene transcription by increasing binding of the 
nuclear transcription factor Spl to its cognate binding site 
[38]. RI R4 contains several consensus Spl binding sites 
and may be regulated by TGF-[3 via this mechanism. In 
models of fibrotic disease, TGF-[3 initiates and perpetuates 
the fibrotic cascade [39]. The up-regulation of RI R4 recep- 
tor expression may amplify fibrotic reactions as part of this 
process. 
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